Literature DB >> 14296027

THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS.

J SHESKIN.   

Abstract

Entities:  

Keywords:  ARSENICALS; DRUG THERAPY; LEPROSY; PLACEBOS; SULFONES; THALIDOMIDE; TOXICOLOGIC REPORT

Mesh：

Substances：

Year:  1965        PMID： 14296027     DOI： 10.1002/cpt196563303

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  97 in total

1.  Thalidomide-induced symptomatic third-degree atrioventricular block.

Authors:  M Hinterseer; A Becker; S Kääb; N Lang; M Näbauer; G Steinbeck
Journal:  Clin Res Cardiol       Date:  2006-06-20       Impact factor: 5.460

2.  Differential effects of thalidomide on angiogenesis and tumor growth in mice.

Authors:  A V Belo; M A Ferreira; A A Bosco; R D Machado; S P Andrade
Journal:  Inflammation       Date:  2001-04       Impact factor: 4.092

Review 3.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

4.  Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day.

Authors:  Maria Stella de Mello Ayres Putinatti; Joel Carlos Lastória; Carlos Roberto Padovani
Journal:  An Bras Dermatol       Date:  2014 Mar-Apr       Impact factor: 1.896

Review 5.  Advancing host-directed therapy for tuberculosis.

Authors:  Robert S Wallis; Richard Hafner
Journal:  Nat Rev Immunol       Date:  2015-03-13       Impact factor: 53.106

Review 6.  Muscle wasting and cachexia in heart failure: mechanisms and therapies.

Authors:  Stephan von Haehling; Nicole Ebner; Marcelo R Dos Santos; Jochen Springer; Stefan D Anker
Journal:  Nat Rev Cardiol       Date:  2017-04-24       Impact factor: 32.419

7.  Resolving a double standard for risk management of thalidomide: an evaluation of two different risk management programmes in Japan.

Authors:  Nobuhiro Ooba; Tsugumichi Sato; Hikaru Watanabe; Kiyoshi Kubota
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

8.  Chemical stabilities and biological activities of thalidomide and its N-alkyl analogs.

Authors:  Colleen Goosen; Timothy J Laing; Jeanetta du Plessis; Theunis C Goosen; Tharaknath B Rao; Gordon L Flynn
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

9.  WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients.

Authors:  C G Iyer; J Languillon; K Ramanujam; G Tarabini-Castellani; J T De las Aguas; L M Bechelli; K Uemura; V Martinez Dominguez; T Sundaresan
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

10.  Treatment of Behçet's disease with thalidomide.

Authors:  M H Hamza
Journal:  Clin Rheumatol       Date:  1986-09       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.